Novartis AG ADR
USUSDNovartis AG ADR (SW:NOVN) — Drug Manufacturers - General. Antal børser, hvor selskabets aktier handles: 6. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om virksomheden
- Websted
- novartis.com
- Sektor
- Healthcare · Drug Manufacturers - General
- Hovedkontor
- BASEL, Switzerland
- Administrerende direktør
- Dr. Vasant Narasimhan M.D.
- Ansatte
- 75 267
- Grundlagt
- 1996
- Udestående aktier
- 1.91 mia. pr. 2025-12-31
- Free float
- 1.86 mia.
- Markedsværdi
- 276.48 mia. USD
- Insidere
- 0.01%
- Institutionelle investorer
- 7.27%
- Branche (SIC)
- Pharmaceutical Preparations
- Juridisk form
- MVII
- ISIN
- CH0012005267
- LEI
- 5493007HIVTX6SY6XD66
- Udbetalingsgrad
- 71.1%
- FCF
- 15.0 mia. USD61%
- Gæld
- 49.0 mia. USD2.6 år FCF
- Udbyttestreak
- 20 år
Beskrivelse
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Børser og tickere
| Børs | Ticker | Valuta | Pris | Type |
|---|---|---|---|---|
| US USA Stocks | NVSEF | USD | 134.22 -0.23% | almindelige aktier |
| MI Borsa Italiana (Milan) | 1NOVN | EUR | 127.6 +1.75% | almindelige aktier |
| SW SIX Swiss Exchange | NOVN | CHF | 119.8 -0.13% | almindelige aktier |
| SW SIX Swiss Exchange | NOVNEE | CHF | 120.02 -1.80% | almindelige aktier |
| VI Vienna Stock Exchange | NOVN | EUR | 126.72 | almindelige aktier |
| XETRA Xetra | NOT | EUR | 126.82 +0.48% | almindelige aktier |
Udbytte
Novartis AG ADR (NOVN) udbetaler udbytte uregelmæssigt. I løbet af de sidste 12 måneder blev der betalt 3.7 CHF pr. Aktie (betalinger: 1). Det svarer til cirka 3.09% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 15.03.2027. Uafbrudt udbyttehistorik: 20 år.
| Ex-dato | Udbetaling | Beløb | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-03-10 | — | 3.7000 CHF | 3.1/6.0 % | årlig | SW:NOVN |
| 2025-03-11 | — | 3.5000 CHF | 2.9/2.9 % | årlig | SW:NOVN |
| 2024-03-07 | — | 3.3000 CHF | 2.8/5.4 % | årlig | SW:NOVN |
| 2023-03-09 | — | 3.2000 CHF | 2.7/2.7 % | årlig | SW:NOVN |
| 2022-03-08 | — | 3.1000 CHF | 2.6/2.6 % | årlig | SW:NOVN |
Nyheder denne uge
Endnu ingen nyheder fra virksomhedens websted.
Største ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| Fisher Asset Management,… | 0.76% | 15.52 mio. | 2026-06-30 |
| Morgan Stanley | 0.43% | 8.73 mio. | 2026-06-30 |
| Dimensional Fund Advisor… | 0.4% | 8.12 mio. | 2026-06-30 |
| Primecap Management Comp… | 0.32% | 6.59 mio. | 2026-06-30 |
| LOOMIS SAYLES & CO L P | 0.26% | 5.24 mio. | 2026-06-30 |
| Bank of America Corporat… | 0.24% | 4.91 mio. | 2026-06-30 |
| VANGUARD CHESTER FUNDS-V… | 0.21% | 4.25 mio. | 2026-06-30 |
| Franklin Resources, Inc. | 0.16% | 3.25 mio. | 2026-06-30 |
| Blackrock Inc. | 0.15% | 3.05 mio. | 2026-06-30 |
| Goldman Sachs Group Inc | 0.15% | 2.98 mio. | 2026-06-30 |
| Northern Trust Corporati… | 0.14% | 2.79 mio. | 2026-06-30 |
| DFA INVESTMENT DIMENSION… | 0.11% | 2.14 mio. | 2026-04-30 |
| LOOMIS SAYLES FUNDS II-L… | 0.07% | 1.42 mio. | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 0.06% | 1.21 mio. | 2026-06-30 |
| Franklin Mutual Series F… | 0.06% | 1.19 mio. | 2026-06-30 |
| JANUS INVESTMENT FUND-Ja… | 0.05% | 949 726 | 2026-06-30 |
| Principal Funds, Inc-Equ… | 0.05% | 945 091 | 2026-04-30 |
| Dimensional ETF Trust-Di… | 0.04% | 888 855 | 2026-04-30 |
| Franklin Mutual Series F… | 0.04% | 812 618 | 2026-06-30 |
| Dimensional ETF Trust-Di… | 0.04% | 716 836 | 2026-04-30 |
